Henagliflozin on Myocardial Fibrosis in Obese Patients (LY2026-317-C)
Effect of Henagliflozin on Myocardial Fibrosis in Obese Patients: A Prospective, Randomized, Controlled Study.
This study evaluates the anti-fibrotic efficacy and safety of henagliflozin versus metformin in non-diabetic obese patients with subclinical myocardial fibrosis, explores whether the benefit is mediated by metabolic improvement or direct myocardial protection, and aims to provide high-level evidence for early pharmacological intervention.
研究概览
详细说明
This study will be based on an established specialized cohort of non-diabetic patients with simple obesity and a multi-omics database. By integrating clinical data with multidimensional information including genomics, metabolomics, and proteomics, patients at high risk of myocardial fibrosis will be identified. After myocardial fibrotic changes are further confirmed by CMR, eligible participants will be randomly assigned to the control group (metformin) or the intervention group (henagliflozin). The treatment period will be 24 weeks, followed by a 24-week safety follow-up period. The difference in the change in the degree of myocardial fibrosis before and after treatment between the two groups will be compared to determine the efficacy of henagliflozin in counteracting myocardial fibrosis in the non-diabetic obese population. This project aims to provide high-level evidence-based medical evidence for targeted pharmacological intervention of obesity-related early cardiac damage, with the goal of improving the long-term prognosis of this population.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Jing Ma
- 电话号码:021-68383420
- 邮箱:majing3436@163.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- BMI ≥ 28 kg/m², or waist circumference ≥ 90 cm in men or ≥ 85 cm in women, or body fat percentage ≥ 25% in men or ≥ 30% in women;
- Adults aged 18 to 65 years;
- ECV greater than 30%;
- No participation in other clinical trials within the past three months.
Exclusion Criteria:
- Diagnosed with diabetes mellitus or prediabetes;
- History of coronary artery disease (coronary stenosis > 50% on coronary angiography or coronary computed tomography), history of myocardial infarction, history of coronary artery bypass grafting or percutaneous coronary intervention; non-ischemic cardiovascular diseases such as idiopathic cardiomyopathy, valvular disease, congenital heart disease, or cor pulmonale; arrhythmia or bundle branch block on electrocardiogram; implantation of a cardiac pacemaker or defibrillator;
- Uncontrolled hypertension: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg during the screening visit (mean of three blood pressure measurements in the supine position);
- Symptomatic hypotension and/or systolic blood pressure < 90 mmHg at V1 or V2, or patients judged by the clinician to have hypovolemia;
- Use within 3 months of: 1) medications that may affect body weight or glucose metabolism, including systemic glucocorticoids (excluding topical, ophthalmic, nasal spray, or inhaled preparations; excluding low-dose or overnight dexamethasone suppression test use), growth hormone, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic/tetracyclic antipsychotic drugs, other psychiatric medications or sedatives (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts), etc.; 2) traditional Chinese medicines, Chinese patent medicines, herbal medicines, health supplements, meal replacements, etc., with weight-loss or glucose-lowering effects; 3) use of or current use of the following weight-loss drugs or drugs containing the following ingredients, such as: sibutramine hydrochloride, orlistat, phentermine, phenylpropanolamine, clobenzorex, fenfluramine, amfepramone, lorcaserin, phentermine/topiramate combination, naltrexone/bupropion combination, etc.; 4) use of glucose-lowering drugs, such as metformin, α-glucosidase inhibitors, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, thiazolidinediones (TZDs), insulin, etc.;
- Other endocrine and metabolic diseases such as hyperthyroidism, hypothyroidism, acromegaly, diabetes insipidus, or Cushing's syndrome;
- Concurrent malignant tumors;
- Severe liver disease (Child-Pugh class C) or liver enzymes (ALT/AST) > 3 times the upper limit of normal;
- Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m²;
- Cognitive impairment, or concomitant infectious or autoimmune diseases;
- History of recurrent urinary or reproductive tract infections;
- Patients who refuse henagliflozin or metformin treatment, or who are allergic to henagliflozin, metformin, or their excipients; those with incomplete questionnaires or incomplete data;
- Pregnant or breastfeeding women.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:干预组
|
Oral henagliflozin 10 mg once daily for 24 weeks, administered at a fixed dose without adjustment. Used in non-diabetic obese patients with subclinical myocardial fibrosis as an off-label investigational treatment. |
|
有源比较器:Control Group
oral metformin tablets 2000 mg/day; or the maximum tolerated dose (≥1000 mg/day). |
Oral metformin titrated to 2000 mg/day (1000 mg twice daily), or the maximum tolerated dose (≥1000 mg/day), for 24 weeks. Dose titration: 500 mg twice daily for weeks 1-2, then 1000 mg twice daily from week 3 if tolerated. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from Baseline in Myocardial Extracellular Volume (ECV) Fraction at 24 Weeks
大体时间:Baseline to Week 24
|
Change from baseline in myocardial extracellular volume (ECV) fraction, as measured by cardiac magnetic resonance (CMR) T1 mapping pre- and post-contrast. ECV is calculated from pre- and post-contrast T1 relaxation times and the patient's hematocrit. The between-group difference in ΔECV (Henagliflozin vs. Metformin) will be compared; continuous data will be summarized as mean ± SD and analyzed using mixed-effects models. |
Baseline to Week 24
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Change from Baseline in Epicardial Adipose Tissue (EAT) Volume at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Left Ventricular Ejection Fraction (LVEF) at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Cardiac Output at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Heart Rate at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Peak Filling Rate at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Stroke Volume Index (BSA-corrected) at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in End-Systolic Volume Index (BSA-corrected) at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in End-Diastolic Volume Index (BSA-corrected) at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Left Ventricular Mass Index (BSA-corrected) at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Early-to-Late Filling Ratio (E/A) at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in LV Mass to End-Diastolic Volume Ratio (MVR) at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Cardiac Index at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Body Weight at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Body Mass Index (BMI) at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Systolic Blood Pressure at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Diastolic Blood Pressure at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Glycated Hemoglobin (HbA1c) at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Fasting Plasma Glucose at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in HOMA-IR (Insulin Resistance Index) at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Total Cholesterol at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in Triglycerides at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
|
Change from Baseline in High-sensitivity CRP (hsCRP) at 24 Weeks
大体时间:Baseline to Week 24
|
Baseline to Week 24
|
其他结果措施
结果测量 |
大体时间 |
|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
大体时间:Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Genitourinary Tract Infections
大体时间:Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Gastrointestinal Adverse Events
大体时间:Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Ketoacidosis
大体时间:Up to 48 Weeks
|
Up to 48 Weeks
|
|
Number of Participants With Serious Adverse Events (SAEs)
大体时间:Up to 48 Weeks
|
Up to 48 Weeks
|
合作者和调查者
赞助
调查人员
- 首席研究员:Jing Ma、Department of Endocrinology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- LY2026-317-C
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.